SG11201811188TA - A buffer free, acid stable low dose volume rotavirus vaccine - Google Patents

A buffer free, acid stable low dose volume rotavirus vaccine

Info

Publication number
SG11201811188TA
SG11201811188TA SG11201811188TA SG11201811188TA SG11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA SG 11201811188T A SG11201811188T A SG 11201811188TA
Authority
SG
Singapore
Prior art keywords
international
vaccine
turkapally
hyderabad
valley
Prior art date
Application number
SG11201811188TA
Other languages
English (en)
Inventor
Krishna Mohan Vadrevu
Sai Devarajulu Prasad
Krishna Murthy Ella
Original Assignee
Bharat Biotech Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech Int Ltd filed Critical Bharat Biotech Int Ltd
Publication of SG11201811188TA publication Critical patent/SG11201811188TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/15Reoviridae, e.g. calf diarrhea virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541Mucosal route
    • A61K2039/542Mucosal route oral/gastrointestinal
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011Details
    • C12N2720/12011Reoviridae
    • C12N2720/12311Rotavirus, e.g. rotavirus A
    • C12N2720/12334Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201811188TA 2016-06-16 2017-06-13 A buffer free, acid stable low dose volume rotavirus vaccine SG11201811188TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641020675 2016-06-16
PCT/IN2017/050237 WO2017216808A1 (en) 2016-06-16 2017-06-13 A buffer free, acid stable low dose volume rotavirus vaccine

Publications (1)

Publication Number Publication Date
SG11201811188TA true SG11201811188TA (en) 2019-01-30

Family

ID=60664101

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201811188TA SG11201811188TA (en) 2016-06-16 2017-06-13 A buffer free, acid stable low dose volume rotavirus vaccine
SG10202012281TA SG10202012281TA (en) 2016-06-16 2017-06-13 A buffer free, acid stable low dose volume rotavirus vaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202012281TA SG10202012281TA (en) 2016-06-16 2017-06-13 A buffer free, acid stable low dose volume rotavirus vaccine

Country Status (22)

Country Link
US (1) US11351245B2 (zh)
EP (1) EP3471768A4 (zh)
JP (1) JP7108549B2 (zh)
KR (3) KR20190020046A (zh)
CN (1) CN109562159B (zh)
AU (1) AU2017285408B2 (zh)
BR (1) BR112018076094A2 (zh)
CA (1) CA3027703A1 (zh)
CO (1) CO2019000078A2 (zh)
EA (1) EA201990027A1 (zh)
GB (1) GB2566244B (zh)
IL (1) IL263740B2 (zh)
JO (1) JOP20180124A1 (zh)
MA (1) MA44557B1 (zh)
MX (1) MX2018015469A (zh)
MY (1) MY198419A (zh)
PH (1) PH12018502650A1 (zh)
SG (2) SG11201811188TA (zh)
TN (1) TN2018000436A1 (zh)
UA (1) UA124430C2 (zh)
WO (1) WO2017216808A1 (zh)
ZA (1) ZA201900176B (zh)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
ATE377428T1 (de) 1996-09-26 2007-11-15 Merck & Co Inc Rotavirus-impfstoff
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
WO1998017785A1 (fr) * 1996-10-18 1998-04-30 The Research Foundation For Microbial Diseases Of Osaka University Antigenes de rotavirus, vaccins et medicaments servant a diagnostiquer l'infection par rotavirus et leurs procedes de preparation
JP4414095B2 (ja) 1998-07-28 2010-02-10 アメリカ合衆国 多価ヒト−ウシ・ロタウイルス・ワクチン
EA005952B1 (ru) 1999-08-17 2005-08-25 Смитклайн Бичем Байолоджикалз С.А. Ослабленная популяция ротавирусов и содержащая ее вакцинная композиция
JP2005038411A (ja) 2003-06-30 2005-02-10 Sony Corp 機器認証情報組込システム、端末機器、機器認証情報処理方法、機器認証情報処理プログラム、提供サーバ、機器認証情報提供方法、機器認証情報提供プログラム、及び記憶媒体
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0516944D0 (en) * 2005-08-17 2005-09-28 Glaxosmithkline Biolog Sa Vaccine
MX2008014391A (es) 2006-05-12 2009-03-06 Bharat Biotech Int Ltd Una composicion util como vacuna.
CN101638638A (zh) * 2008-07-29 2010-02-03 辽宁依生生物制药有限公司 人猪重配轮状病毒
EP2453917B1 (en) 2009-07-13 2015-07-22 Bharat Biotech International Limited A composition useful as rotavirus vaccine and a method therefor.
CN103747800A (zh) * 2011-04-28 2014-04-23 国际医学基金会 液体疫苗制剂
JP6126684B2 (ja) 2012-04-23 2017-05-10 バハラ バイオテック インターナショナル リミテッド 新規なロタウイルスワクチン組成物及び同組成物を調製する方法

Also Published As

Publication number Publication date
US20190142932A1 (en) 2019-05-16
AU2017285408B2 (en) 2024-05-02
MX2018015469A (es) 2019-04-24
IL263740B2 (en) 2024-01-01
CO2019000078A2 (es) 2019-01-18
MA44557B1 (fr) 2021-11-30
KR20190020046A (ko) 2019-02-27
JP2019518056A (ja) 2019-06-27
ZA201900176B (en) 2019-09-25
MY198419A (en) 2023-08-29
GB201900562D0 (en) 2019-03-06
MA44557A1 (fr) 2020-01-31
EP3471768A1 (en) 2019-04-24
JOP20180124A1 (ar) 2019-01-30
US11351245B2 (en) 2022-06-07
KR20230125863A (ko) 2023-08-29
EP3471768A4 (en) 2020-03-04
EA201990027A1 (ru) 2019-07-31
GB2566244B (en) 2021-10-13
GB2566244A (en) 2019-03-06
TN2018000436A1 (en) 2020-06-15
CN109562159A (zh) 2019-04-02
PH12018502650A1 (en) 2019-10-07
UA124430C2 (uk) 2021-09-15
IL263740A (en) 2019-01-31
KR20220063302A (ko) 2022-05-17
CN109562159B (zh) 2022-10-28
IL263740B1 (en) 2023-09-01
CA3027703A1 (en) 2017-12-21
SG10202012281TA (en) 2021-01-28
JP7108549B2 (ja) 2022-07-28
WO2017216808A1 (en) 2017-12-21
BR112018076094A2 (pt) 2019-03-26
AU2017285408A1 (en) 2019-01-31

Similar Documents

Publication Publication Date Title
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811150WA (en) Ev-mediated delivery of binding protein-small molecule conjugates
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201902949PA (en) Pharmaceutical compositions and methods of treating cardiovascular diseases
SG11201809100QA (en) Use of gram negative species to treat atopic dermatitis
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201809534UA (en) Methods of treating autoimmune disease using allogeneic t cells
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof
SG11201901048VA (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
SG11201804961UA (en) Formulations with reduced degradation of polysorbate
SG11201805755SA (en) Methods of administering hepcidin
SG11201804587QA (en) Isoindole compounds
SG11201906616VA (en) Nasal pharmaceutical compositions for reducing the risks of exposure to air pollutants
SG11201807023QA (en) Compositions and methods for preventing and/or treating vitamin b12 deficiency
SG11201806127XA (en) Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate
SG11201803816RA (en) Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease